Friday, April 4, 2025

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Related stories

Cyberhaven secures $100M Series D for AI data security

Cyberhaven, a leader in data detection and response (DDR),...

Kong AI Gateway Unveils Advanced AI Governance Tools

Kong Inc., a pioneer in cloud API technologies, has...

Informatica Launches AI Cloud Integration & MDM

New generative AI-powered features boost developer productivity, accelerate enterprise...

Skai Launches Celeste AI, a GenAI Agent for Commerce Media

Skai, a leader in omnichannel commerce media solutions, has...

Centrilogic & CrewAI Partner to Boost AI Adoption in Canada

Centrilogic, a global provider of IT transformation solutions, has...
spot_imgspot_img

Precision Neuroscience Corporation (Precision) announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

An expert in chip design for low-power electronics, Dr. Otis is one of the leading technologists working in the medical field. He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022. He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.

Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners. With Dexcom, Otis’ team helped develop the groundbreaking G7 continuous glucose monitor for diabetes. Additionally, he partnered with Novartis/Alcon on smart optical devices, and with GlaxoSmithKline on the joint venture Galvani to treat chronic diseases.

Also Read: Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

At Precision, Otis will lead the team developing the company’s brain–computer interface implant, which is designed to treat severe paralysis caused by conditions such as spinal cord injury and ALS, restoring functions including speech and movement.

“After Verily, I spent a year and a half exploring opportunities,” Otis said. “After researching many different techniques to tackle brain–computer interfaces, I became convinced that Precision’s approach of using high-resolution surface electrodes is the right one to bring a powerful product to market. I’m excited to be part of the team that is going to build and scale the first mass-produced version of this technology.”

Prior to Alphabet/Verily, Otis was a tenured professor at the University of Washington’s Department of Electrical and Computer Engineering, where he pioneered techniques for creating highly miniaturized wearable, implantable, and on-eye wireless sensors. He has authored over 50 patents and 100 peer-reviewed papers in the fields of biosignal interfaces and low-power wireless integrated circuit design. Otis received his MS and Ph.D. in electrical engineering from the University of California, Berkeley.

SOURCE: GlobeNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img